BUSINESS

Stock-Out of Mucosolate, Lemalc Due to Non-Conformance Results of Dissolution Testing, Stable Supply to Resume Next Spring: Teva Pharma Japan

October 31, 2013
Teva Pharma Japan has revealed that a stock-out for the extended-release expectorant Mucosolate L Cap.45 (ambroxol) and the anti-rheumatoid treatment Lemalc Tab. 100 (bucillamine) was due to the non-conformance results of dissolution testing conducted at the company prior to shipment.…

To read the full story

BUSINESS

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

By Ken Yoshino

Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…

By Philip Carrigan

We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…